This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Terminal Insomnia
Information about Terminal Insomnia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Terminal Insomnia
Most recent studies have shown that Terminal Insomnia shares some biological mechanisms with agitation, anxiety-disorders, depressive-disorder, depressive-symptom, difficulty-sleeping, excessive-daytime-somnolence, initial-insomnia, major-depressive-disorder, melancholic-depression, mental-disorders, middle-insomnia, mood-disorders, multiple-acyl-coenzyme-a-dehydrogenase-deficiency, nightmare-disorder, pain, sleep-apnea-syndromes, sleep-disorders, sleep-initiation-and-maintenance-disorders, sleeplessness, snoring.
Among the many pathways, these few ones have gauged particular interests from scientists studying Terminal Insomnia, and have been seen in publications frequently: Acid Secretion, Aging, Circadian Rhythm, Cortisol Secretion, Excretion, Flight, Gastric Emptying, Habituation, Lactation, Menopause, Pathogenesis, Peristalsis, Prolactin Secretion, Response To Stress, Secretion, Sensitization
Quite a number of genes have been found to play important roles in Terminal Insomnia, such as BRD2, CCAR1, DST, ETFA, EXOSC10, HTT, IL6, LIFR, MUC1, NDUFB6, PER2, PNPLA6, POMC, PRB1, PRL, PTH, REM1, TNFSF14, TRH. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.